BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.5//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261005
DTEND;VALUE=DATE:20261009
DTSTAMP:20260528T110955Z
CREATED:20260528T110955Z
LAST-MODIFIED:20260528T110955Z
UID:43630-1791158400-1791503999@www.pharmajournalist.com
SUMMARY:16th World Clinical Biomarkers & Companion Diagnostics Summit
DESCRIPTION:Fueled by surging digital pathology partnerships\, improved MRD sensitivity and high-plex single‑cell and multi‑omic profiling to breakthroughs\, the precision medicine field is evolving rapidly. \nBuilding on this momentum\, the 16th World Clinical Biomarkers & Companion Diagnostics Summit returns to Boston this fall\, uniting 850+ senior stakeholders in the common goal of advancing timely\, accessible and affordable precision medicine to patients in need. \nBe the first to access our new event program: https://ter.li/5c0adwgh \nJoin industry-leading peers from biopharma\, diagnostics\, testing labs\, and regulatory bodies\, to unpack fit-for-purpose CDx strategies\, spark new co-development partnerships\, discover cutting-edge genomic sequencing\, pathology\, multi-omic\, single cell and multimodal innovations. \nThis year’s agenda will expand to five dedicated tracks of content to ensure your entire team leave equipped with the tools and insights to tackle the specific challenges facing them at their stage of development. \n\nBiomarker Discovery & Translation\nClinical & CDx Development\nRx-Dx Commercialization & Adoption\nDigital Pathology & Spatial Biomarkers (BRAND-NEW)\nMultimodal & AI‑Enabled Endpoints (BRAND-NEW)\n\nGrasp the opportunity to attend the industry’s leading touchpoint for drug-diagnostic co-development advancement. \nTogether let’s translate promising precision medicine into scalable\, equitable drug-diagnostic therapies for patients across oncology\, neurological\, autoimmune\, rare and chronic diseases. \nSign up today: https://ter.li/0jb66uvu \nRegistration is FREE* for drug developers and researchers.  \n*Subject to terms and conditions visit the website to learn more.
URL:http://www.pharmajournalist.com/event/16th-world-clinical-biomarkers-companion-diagnostics-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261012
DTEND;VALUE=DATE:20261016
DTSTAMP:20260512T103447Z
CREATED:20260512T103447Z
LAST-MODIFIED:20260512T103447Z
UID:43484-1791763200-1792108799@www.pharmajournalist.com
SUMMARY:17th World ADC San Diego
DESCRIPTION:Returning as the largest and definitive ADC congress\, the 17th World ADC San Diego is THE one-stop bioconjugate shop\, bringing together the global ADC community for an unparalleled amalgamation of case studies\, development trends and networking opportunities to forge ADC innovation into differentiated\, early-line patient outcomes. \nWith 7 streams of end-to-end ADC content across Discovery Chemistry\, Discovery Biology\, Preclinical\, Translational Medicine\, Clinical Lessons\, Process & Analytical Development\, and Manufacturing & Supply\, all ADC innovation will be in the spotlight for an unmissable week of data and insights to de-risk future ADC development and push ADCs into earlier line oncology treatments. \nUniting 1\,300 industry senior enthusiasts from biopharma\, innovative start-ups\, leading service providers and academic\, physician and regulator KOLs\, World ADC San Diego is the place to discuss\, debate and advance the future of ADC development. \nFeaturing 170+ senior presenters\, a snapshot of the 2026 speaker faculty includes: \n\nSuzanne Edavettal\, Vice President\, Research & Head\, Protein Therapeutics\, Amgen\nVinod Bulusu\, Executive Director\, Product Stewardship Lead\, AstraZeneca\nGiorgia Vicentini\, Vice President\, Global Program Lead\, Oncology\, Bristol Myers Squibb\nRonald Fleming\, Executive Director\, Clinical Development\, Daiichi Sankyo\nGail Lewis\, Distinguished Scientist\, Discovery Oncology\, Genentech\nMin Hu\, Senior Vice President\, Discovery\, Innovent Biologics\nBob Lutz\, Chief Scientific Officer\, Iksuda Therapeutics\nJeffrey Settleman\, Chief Scientific Officer\, Oncology R&D\, Pfizer\nDominik Schumacher\, Chief Executive Officer\, Tubulis\nRita Nanda\, Associate Professor\, Medicine & Director\, Breast Oncology\, Section of Hematology/Oncology\, University of Chicago\n\nView the full list of speaking companies: https://ter.li/xsz013cs \nIf you want to stay competitive in the field\, you cannot miss World ADC San Diego to de-risk future ADC development and push ADCs to earlier-line oncology treatments.
URL:http://www.pharmajournalist.com/event/17th-world-adc-san-diego/
LOCATION:Town & Country San Diego\, 500 Hotel Circle\, North San Diego\, San Diego\, CA\, 92108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261019
DTEND;VALUE=DATE:20261022
DTSTAMP:20260617T114733Z
CREATED:20260617T114733Z
LAST-MODIFIED:20260617T114733Z
UID:43761-1792368000-1792627199@www.pharmajournalist.com
SUMMARY:5th Operationalise: Early Access Programmes Summit Europe
DESCRIPTION:Early Access Programmes have evolved into a critical\, but increasingly complex\, part of drug development and launch strategy. What was once a reactive pathway is now a strategic lever shaping timelines\, evidence generation\, and patient access across global markets. \nThe 5th Operationalise: Early Access Programmes Summit Europe is built for the teams responsible for turning that strategy into execution. As regulatory expectations shift\, reimbursement timelines extend\, and programmes scale globally\, organisations must make more decisions\, earlier\, and with greater consequence. \nThis is the only European forum dedicated to the operational reality of early access – bringing together 140+ leaders across Medical Affairs\, Access\, Regulatory\, Clinical Operations\, and Supply to share how programmes are being designed\, adapted\, and delivered in practice. \nWhether you are building your first programme\, scaling across regions\, or managing a global access portfolio\, this is your opportunity to benchmark your approach\, challenge your assumptions\, and leave with the insight needed to make smarter decisions and deliver earlier\, sustainable access for patients in 2026 and beyond. \nFor more information and to register online\, please click here.
URL:http://www.pharmajournalist.com/event/5th-operationalise-early-access-programmes-summit-europe/
LOCATION:Park Plaza Victoria London\, 239 Vauxhall Bridge Road Pimlico\, London\, SW1V 1EQ\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261020
DTEND;VALUE=DATE:20261023
DTSTAMP:20260630T110639Z
CREATED:20260630T110639Z
LAST-MODIFIED:20260630T110639Z
UID:43858-1792454400-1792713599@www.pharmajournalist.com
SUMMARY:4th Covalent Drug Discovery & Development Summit
DESCRIPTION:4th Covalent Drug Discovery & Development Summit (October 20–22\, Boston\, MA) \nCovalent drug discovery is entering a defining era. Once constrained by safety and selectivity concerns\, advances in chemistry\, screening technologies\, and translational science are unlocking covalent approaches as a powerful strategy to target previously inaccessible biology. \nAs the field evolves\, the challenge is no longer proving potential. The priority is successful clinical translation. From predicting off-target toxicity to optimizing PK/PD and dose selection\, teams continue to face uncertainty when moving from discovery into the clinic. Many programs still encounter critical gaps in translating promising preclinical data into patient outcomes. \nThe 4th Covalent Drug Discovery & Development Summit is the only industry-led forum dedicated to bridging discovery through to clinical application. Designed to unite medicinal chemists\, chemical biologists\, translational scientists\, and early clinical leaders\, the meeting delivers a truly end-to-end perspective across covalent drug development\, now with expanded clinical content reflecting the growing pipeline of first-in-human and Phase II programs. \nAcross two conference days and interactive workshops\, attendees will gain practical\, actionable insights to: \n\nDesign safer\, more selective covalent compounds using novel warheads and structure-guided approaches\nDe-risk development through advanced toxicity\, reactivity\, and safety assessment strategies\nIntegrate translational data to improve in vitro to in vivo correlation and support confident clinical decisions\nExpand the druggable space by targeting new residues and previously undruggable biology\n\nWith case studies spanning AI-driven discovery\, chemoproteomics\, kinetic assays\, and translational workflows\, the summit showcases how the field is moving beyond traditional targets and into next-generation covalent therapies. \nBringing together 80+ senior leaders from pharma\, biotech\, and academia\, this is a highly curated environment for deep technical exchange\, collaboration\, and real-world problem solving. \nWhether you are optimizing discovery\, scaling translational strategy\, or preparing for the clinic\, this is the critical forum to understand what it truly takes to move covalent therapies from concept to clinic and to help shape the next wave of precision medicines.
URL:http://www.pharmajournalist.com/event/4th-covalent-drug-discovery-development-summit/
LOCATION:Hampton Inn Boston Seaport District\, 670 Summer St\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261026
DTEND;VALUE=DATE:20261030
DTSTAMP:20260609T083754Z
CREATED:20260609T083754Z
LAST-MODIFIED:20260609T083754Z
UID:43704-1792972800-1793318399@www.pharmajournalist.com
SUMMARY:9th TPD & Induced Proximity Summit
DESCRIPTION:After a decade of innovation\, the TPD field has its first drug approval in the form of Arvinas’ Veppanu. Combined with the recovering market of 2026\, this clinical validation will unleash a new wave of innovative approaches and push TPD to a new inflection point. Already\, the headwinds are reversing with $15B worth of upfront deals involving TPD candidates and companies in 2026 alone. \nHowever\, following the risk-averse funding environment of 2025\, continued positive clinical data is key to regaining investor confidence and pharma interest. That’s why the 9th TPD & Induced Proximity Summit is returning as the globe’s definitive forum to help you gain that ever-important clinical validation. As the world’s largest and most comprehensive TPD conference featuring the latest data from early discovery to clinical development\, it is designed to help you discover the best novel targets\, optimize your degrader profile\, and accelerate your pipelines to the clinic and beyond. \nView the full event guide.
URL:http://www.pharmajournalist.com/event/9th-tpd-induced-proximity-summit/
LOCATION:The Omni Boston Hotel at the Seaport\, 450 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR